DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 1, 2026
- Amount
- Program total $2.7M
- Closes
- Oct 22, 2026 (in 40 days)
Similar opportunities open now
- DoW Tick-Borne Disease Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 40 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 18 days
- DoW Toxic Exposures Investigator Initiated Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 68 days
- DoW Toxic Exposures Translational Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 68 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 18 days
Classification and identifiers
- Solicitation number
- HT942526TBDRPTDRA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $2.7M
Who can apply
About this opportunity
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings. https://cdmrp.health.mil/pubs/press/2026/tbdrppreann